Prison ADHD drug trial aims to cut recidivism and violence
NCT ID NCT05842330
First seen Mar 29, 2026 · Last updated May 05, 2026 · Updated 7 times
Summary
This study tests whether a common ADHD medication (OROS-methylphenidate) can help prisoners with ADHD manage their symptoms and reduce problem behaviors like fights, self-harm, and rule-breaking. About 150 adults in French prisons will receive either the drug or a placebo for several months. The goal is to see if treatment improves attention, impulse control, and lowers the risk of re-offending after release.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADHD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Geneva University Hospitals
RECRUITINGGeneva, Canton of Geneva, 1211, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.